Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $13 | $8 |
| - Cash | $0 | $2 | $1 | $2 |
| + Debt | $2 | $0 | $4 | $2 |
| Enterprise Value | $5 | $0 | $16 | $8 |
| Revenue | $2 | $1 | $1 | $2 |
| % Growth | 41.7% | 6.7% | -44.6% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 54.8% | 74.8% | 77.4% | 58.5% |
| EBITDA | -$5 | -$9 | -$13 | -$24 |
| % Margin | -264.6% | -744.3% | -1,091.4% | -1,135.6% |
| Net Income | -$5 | -$10 | -$14 | -$25 |
| % Margin | -274% | -817.1% | -1,141.3% | -1,157.9% |
| EPS Diluted | -0.72 | -1.78 | -2.66 | -5.6 |
| % Growth | 59.6% | 33.1% | 52.5% | – |
| Operating Cash Flow | -$3 | -$4 | -$5 | -$9 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$3 | -$4 | -$5 | -$9 |